Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug may be used to treat women with ovarian cancer

21.04.2005


A new drug, RAD001, has been shown to stop the growth and movement of certain ovarian cancer cells, according to scientists at Fox Chase Cancer Center in Philadelphia. The research was presented today at the 96th Annual Meeting of the American Association for Cancer Research (AACR) in Anaheim, Calif.



A large percentage of human cancers have high activity levels of an enzyme known as AKT. This enzyme controls a number of cell functions, including cell size, division and response to chemotherapy.

"The AKT signaling pathway is overly active in a wide variety of different cancers, including ovarian carcinoma, so we and others think that this pathway is an attractive target for cancer treatment at the molecular level," said Joseph Testa, Ph.D., director of the Human Genetics Program at Fox Chase. "However, because the AKT pathway is involved in so many cell processes, many of them beneficial, we were looking to control some of the proteins downstream from AKT so we didn’t inhibit the good processes."


RAD001 is a derivative of rapamycin, a drug used as an immunosuppressant. RAD001 targets an enzyme known as mTOR (mammalian target of rapamycin). In mice injected with human ovarian cancer cells with high AKT activity, the researchers found that RAD001 arrested the cells so they couldn’t divide (reproduce) or move to another location in the body (metastasize). The drug also reduced the cancer cells’ ability to make blood vessels to nourish themselves (angiogenesis). In cancer cells with low levels of AKT activity, RAD001 had minimal effect.

Testa speculates that after being immobilized by RAD001, ovarian cancer cells could be vulnerable to chemotherapy that would kill the cells while their reproductive properties are weakened.

"Ovarian cancer is the leading cause of gynecologic cancer deaths," Testa said. "It usually isn’t detected until it’s quite advanced and is hard to treat. This is one drug that is well-tolerated and could be useful in ovarian cancer treatment."

Colleen Kirsch | EurekAlert!
Further information:
http://www.fccc.edu

More articles from Life Sciences:

nachricht One step closer to reality
20.04.2018 | Max-Planck-Institut für Entwicklungsbiologie

nachricht The dark side of cichlid fish: from cannibal to caregiver
20.04.2018 | Veterinärmedizinische Universität Wien

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>